1Gheorghiade M,Teerlink JR,Mebazaa A.Pharmacology of new agents for the acute heart failure syndrome[J].Am J Cardiol,2005,96(6A):68G-73G. 被引量：1
2Kaheinen P,Pollesello P,Levijoki J.Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart[J].J Cardiovas Pharmacol,2004,43(4):555-561. 被引量：1
3Endoh M.Changes in intracellular Ca^2+ mobilization and Ca^2+ sensitization as mechanisms of action of physiological interventions and inotropic agents intact myocardial cells[J].Jpn Heart J,1998,39(6):1-44. 被引量：1
4Kaheinenp,Pollesello P,Levisjoki J,et al.Levosimendan increased diastolic cornary flow in isolated guinea-pig heart by opening ATP-sensitve potassium channels[J].J Cardiovasc Pharmacol,2001,37(4):367-374. 被引量：1
5Akao M,Ohler A,O,Rourke B.Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells[J].Circ Res,2001;88:1267-1275. 被引量：1
6Paraskevaidis IA,Parissis JT,Kremastions D.Anti-infammatory and anti-apoptotic effects of levosimendan in decomensated heart failure:a novel mechnism of drug-induced improvement in contractile performance of the failing heart[J].Curr Med Chem Cardiovasc Hematol Agent,2005,3(3):243-247. 被引量：1
7Derenllis J,Panareton W.Effects of levosimendan on restrictive left ventricular filling in severe heart failure; a combinated hemodynamic and Doppler echocardiograghic study[J].Chest,2005,128(4):2633-2639. 被引量：1
8Avgeeropoulon,Andreadou I.The Ca^2+ sensitizer levosimendan improve oxidagtive damage,BNP and pro-inflammatory cytokine level in patients with advanced decompensated heart failure in comparison to dobutamine[J].Eur J Heart Fail,2005,7(5):882-887. 被引量：1
9Nieminen MS,Akkila J,Hasenfuss G,et al.Hemodynamic and neurohumoral effects of continuous infusion of levosimendan inpatients with congestive heart failure[J].J Am Coll Cardiol,2000,36(6):1903-1912. 被引量：1
10Slawsky MT,Colucci WS,Gottlieb SS,et al.Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure study Investigators[J].Circulation,2000,102(18):2222-2227. 被引量：1
同被引文献7
1Gheorghiade M, Teerlink JR, Mebazaa A. Pharmacology of new agents for the acute heart failure syndrome [ J ]. Am J Cardiol, 2005, 96 (6A) : 68 -73. 被引量：1
2Maurelet JD, Liu PT. B - type natriuretic peptide in the management of heart failure [J]. Hongkong Med J, 2008, 14: 216-219. 被引量：1
